201 related articles for article (PubMed ID: 20716806)
1. Biomarker-based prediction of response to therapy for colorectal cancer: current perspective.
Ross JS; Torres-Mora J; Wagle N; Jennings TA; Jones DM
Am J Clin Pathol; 2010 Sep; 134(3):478-90. PubMed ID: 20716806
[TBL] [Abstract][Full Text] [Related]
2. Biomarker-based selection of therapy for colorectal cancer.
Ross JS
Biomark Med; 2011 Jun; 5(3):319-32. PubMed ID: 21657841
[TBL] [Abstract][Full Text] [Related]
3. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
4. Personalized treatment for patients with colorectal cancer: role of biomarkers.
Duffy MJ
Biomark Med; 2015; 9(4):337-47. PubMed ID: 25808438
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.
To KK; Tong CW; Wu M; Cho WC
World J Gastroenterol; 2018 Jul; 24(27):2949-2973. PubMed ID: 30038463
[TBL] [Abstract][Full Text] [Related]
6. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
8. Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.
Włodarczyk M; Włodarczyk J; Siwiński P; Sobolewska-Włodarczyk A; Fichna J
Curr Drug Targets; 2018; 19(15):1731-1737. PubMed ID: 30073926
[TBL] [Abstract][Full Text] [Related]
9. Non-coding RNAs Enabling Prognostic Stratification and Prediction of Therapeutic Response in Colorectal Cancer Patients.
Perakis SO; Thomas JE; Pichler M
Adv Exp Med Biol; 2016; 937():183-204. PubMed ID: 27573901
[TBL] [Abstract][Full Text] [Related]
10. [Molecular biology in clinical cancer research: the example of digestive cancers].
Lièvre A; Laurent-Puig P
Rev Epidemiol Sante Publique; 2005 Jun; 53(3):267-82. PubMed ID: 16227914
[TBL] [Abstract][Full Text] [Related]
11. Implementing prognostic and predictive biomarkers in CRC clinical trials.
Van Schaeybroeck S; Allen WL; Turkington RC; Johnston PG
Nat Rev Clin Oncol; 2011 Feb; 8(4):222-32. PubMed ID: 21321566
[TBL] [Abstract][Full Text] [Related]
12. New trends in molecular and cellular biomarker discovery for colorectal cancer.
Aghagolzadeh P; Radpour R
World J Gastroenterol; 2016 Jul; 22(25):5678-93. PubMed ID: 27433083
[TBL] [Abstract][Full Text] [Related]
13. Predictive biomarkers for response to therapy in advanced colorectal/rectal adenocarcinoma.
Kapur P
Crit Rev Oncog; 2012; 17(4):361-72. PubMed ID: 23176043
[TBL] [Abstract][Full Text] [Related]
14. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
15. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
[TBL] [Abstract][Full Text] [Related]
16. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
Bhushan S; McLeod H; Walko CM
Clin Colorectal Cancer; 2009 Jan; 8(1):15-21. PubMed ID: 19203892
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer.
Ma H; Chen G; Guo M
Proteomics Clin Appl; 2016 Apr; 10(4):503-15. PubMed ID: 26616366
[TBL] [Abstract][Full Text] [Related]
18. Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.
Lam M; Loree JM; Pereira AAL; Chun YS; Kopetz S
Curr Treat Options Oncol; 2018 Feb; 19(2):11. PubMed ID: 29488033
[TBL] [Abstract][Full Text] [Related]
19. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
[TBL] [Abstract][Full Text] [Related]
20. Actionable Potentials of Less Frequently Mutated Genes in Colorectal Cancer and Their Roles in Precision Medicine.
Mohd Yunos RI; Ab Mutalib NS; Tieng FYF; Abu N; Jamal R
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32245111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
